Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Current oncology

S.F. Wang¹  L.J. Jiao²  J. Zhang³  R.X. Zhang⁴  L. Xu⁵  Y. Zhong⁶  Q. Wang⁷ 

[1] Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine;Shanghai Hospital of Integrated Traditional Chinese Medicine;Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine;Fudan University Shanghai Cancer Center;University of Maryland;Yueyang Hospital of Integrated Traditional Chinese Medicine;Yueyang Hospital of Integrated Traditional Chinese Medicine

关键词: Traditional Chinese Medicine;    non-small-cell lung cancer;    advanced;    maintenance therapy;    integrative oncology;   

DOI  :  10.3747/co.24.3561

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

BackgroundThe concept of maintenance therapy in cancer treatment is currently under debate because of modest survival benefits, added toxicity, economic considerations, and quality-of-life concerns. Traditional Chinese Medicine (tcm) is widely used in China for cancer patients, offering the advantages of low toxicity and enhancement of quality of life. However, no systematic reviews or meta-analyses have assessed the role of tcm as maintenance treatment for non-small-cell lung carcinoma. MethodsWe searched the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, PubMed, embase, and the Cochrane Library databases for all eligible studies. The endpoints were overall survival (os), progression-free survival (pfs), the 1-year and 2-year survival rates, and performance status. Our meta-analysis used a fixed-effects model and a random-effects model for heterogeneity in the Stata software application (version 11.0: StataCorp LP, College Station, TX, U.S.A.), with the results expressed as hazard ratios (hrs) or risk ratios (rrs), with their corresponding 95% confidence intervals (95% cis). ResultsSixteen randomized studies representing 1150 patients met the inclusion criteria. Compared with best supportive care, observation, or placebo, tcm as maintenance treatment was associated with a significant increase in os (hr: 0.49; 95% ci: 0.35 to 0.68;p< 0.001), pfs (hr: 0.66; 95% ci: 0.51 to 0.84;p= 0.001), and 2-year survival rate (rr: 0.63; 95% ci: 0.44 to 0.92,p= 0.017), and a significant improvement in performance status (rr: 0.68; 95% ci: 0.61 to 0.75;p< 0.001). ConclusionsFor patients who show non-progression—including stable disease, partial response, or complete response—after first-line chemotherapy, including those with poor quality of life, oral Chinese herbal medicine can be considered an efficient and safe maintenance therapy strategy.

【 授权许可】

Unknown